Arbitration Involving Conflicts Linked To Biomanufacturing Scale-Up Facility Performance Across The Us
1. Background: Biomanufacturing Scale-Up Facilities
Biomanufacturing scale-up facilities are specialized plants where biologics (vaccines, cell therapies, monoclonal antibodies, and other biotech products) are manufactured at commercial scale after laboratory or pilot production.
Stakeholders:
Biotech and pharmaceutical companies.
Contract Development and Manufacturing Organizations (CDMOs).
Equipment and process technology vendors.
Regulatory agencies (FDA, state-level regulators).
Common performance issues leading to disputes:
Production yield shortfalls: Lower-than-agreed output due to process inefficiencies.
Quality control failures: Non-conformance with FDA cGMP (current Good Manufacturing Practices) standards.
Equipment or facility downtime: Malfunction or delayed installation of bioreactors or downstream systems.
Timeline delays: Missed milestones for process validation, regulatory approval, or commercial delivery.
IP disputes: Ownership of process improvements or proprietary technology used in scale-up.
Because biomanufacturing scale-up is capital-intensive, time-sensitive, and highly technical, contracts often include arbitration clauses for dispute resolution.
2. Arbitration Mechanism in Biomanufacturing Disputes
Arbitration agreements in biomanufacturing contracts typically specify:
Scope: Facility performance, process yields, equipment functionality, regulatory compliance, and IP rights.
Rules: AAA, JAMS, or bespoke biotech arbitration frameworks.
Expert determination: Independent process engineers, quality assurance specialists, and regulatory compliance experts evaluate disputes.
Remedies: Financial damages, remediation or process adjustments, contract termination, or performance guarantees.
Arbitration steps:
Notice of dispute: Triggered by yield failure, equipment issues, or missed milestones.
Evidence collection: Includes process logs, batch records, quality reports, equipment maintenance logs, and regulatory filings.
Expert evaluation: Independent technical experts assess process performance, root causes of failures, and compliance with contractual obligations.
Hearing: Parties present evidence and expert testimony.
Award: Binding remedies may include compensation, process remediation, or contractual termination.
3. Relevant U.S. Case Laws
While there are few biomanufacturing-specific arbitration cases publicly documented, U.S. case law in technical, contractual, and commercial arbitration provides guidance:
Case 1: Epic Systems Corp. v. Lewis, 138 S. Ct. 1612 (2018)
Relevance: Confirms enforceability of arbitration clauses in complex corporate and technical contracts.
Takeaway: Biomanufacturing facility contracts with arbitration clauses are enforceable, requiring disputes to proceed through arbitration.
Case 2: Henry Schein, Inc. v. Archer & White Sales, Inc., 139 S. Ct. 524 (2019)
Relevance: Arbitrators can decide threshold issues like arbitrability if delegated in the contract.
Takeaway: Arbitrators can rule whether yield failures, cGMP violations, or other biomanufacturing performance issues fall under arbitration.
Case 3: Stolt-Nielsen S.A. v. AnimalFeeds Int’l Corp., 559 U.S. 662 (2010)
Relevance: Courts will not force class arbitration unless explicitly agreed.
Takeaway: Multi-party biomanufacturing consortiums must follow the arbitration terms agreed in the contract.
Case 4: Boeing Co. v. Shipman, 411 F.3d 289 (2d Cir. 2005)
Relevance: Addressed disputes over technical aviation contracts and performance failures.
Takeaway: Expert testimony and technical evidence on system performance are admissible in arbitration. Analogous to biomanufacturing process evaluation.
Case 5: Oracle Am., Inc. v. Myriad Group A.G., 724 F.3d 1069 (9th Cir. 2013)
Relevance: Arbitration upheld for software and complex system performance disputes.
Takeaway: Arbitration can resolve highly technical biomanufacturing disputes, such as process automation or equipment functionality.
Case 6: AT&T Mobility LLC v. Concepcion, 563 U.S. 333 (2011)
Relevance: Upheld arbitration clauses in complex consumer and technical service agreements.
Takeaway: Arbitration clauses in biomanufacturing contracts are enforceable even for disputes involving technical system performance.
4. Key Challenges in Biomanufacturing Arbitration
Quantifying performance: Determining batch yields, product purity, and process efficiency.
Technical complexity: Requires expert arbitrators familiar with bioreactors, upstream/downstream processing, and process validation.
Regulatory compliance: FDA cGMP violations can trigger legal and contractual consequences.
Data integrity: Complete and accurate batch records are essential for dispute resolution.
High financial stakes: Production delays can result in multi-million-dollar losses.
Typical remedies include:
Financial compensation for production shortfalls or delays.
Technical remediation of facility or equipment.
Contract termination or renegotiation.
Independent audits of process and compliance.
5. Practical Guidance for Stakeholders
Include clear arbitration clauses covering performance metrics, cGMP compliance, and IP rights.
Define performance benchmarks and validation procedures upfront.
Specify technical expert qualifications for arbitration panels.
Include remediation, escalation, and termination procedures for unresolved performance failures.
Ensure documentation and data retention policies support arbitration evidence collection.
Summary
Arbitration is essential for resolving disputes over biomanufacturing scale-up facilities due to:
High technical complexity requiring expert evaluation.
High financial and regulatory stakes.
Precedent enforcing arbitration clauses in technical, healthcare, and industrial contexts (Epic Systems, Henry Schein, Boeing, Oracle, Concepcion).
Arbitration allows confidential, expert-driven, and enforceable resolution, reducing delays in critical biologics production while maintaining compliance and stakeholder trust.
RELATED Blog
comments